AI-engineered candidates
Alzheimer's Disease
Key Facts
About Owl Therapeutics
Owl Therapeutics is a private, preclinical-stage biotech pioneering a novel approach to neurological diseases by focusing on microglial enhancement. Its core strategy combines a proprietary generative AI platform for drug design with biomarker-driven precision medicine to increase development efficiency. The company has established key partnerships, including a licensing and clinical collaboration with Abliva for NeuroSTAT® in TBI, and is led by a team with deep experience from major biopharma firms like Genentech. Owl is positioning itself at the intersection of AI-driven drug discovery and the high-need neuroimmunology space.
View full company profileAbout Owl Therapeutics
Owl Therapeutics is a private, preclinical-stage biotech pioneering a novel approach to neurological diseases by focusing on microglial enhancement. Its core strategy combines a proprietary generative AI platform for drug design with biomarker-driven precision medicine to increase development efficiency. The company has established key partnerships, including a licensing and clinical collaboration with Abliva for NeuroSTAT® in TBI, and is led by a team with deep experience from major biopharma firms like Genentech. Owl is positioning itself at the intersection of AI-driven drug discovery and the high-need neuroimmunology space.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |